PDF (12.5 MB)
Collect
Submit Manuscript
Research Article | Open Access

Three-year outcomes of patients with non-valvular atrial fibrillation: the COOL-AF registry

Rungroj Krittayaphong1()Satchana Pumprueg1Pontawee Kaewkumdee1Ahthit Yindeengam1Gregory YH Lip2
Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Show Author Information

Abstract

BACKGROUND

Clinical outcomes of patients with non-valvular atrial fibrillation (AF) in Asian populations may be different from non-Asians. In this study, we aimed to determine the incidence of ischemic stroke/systemic embolism (SSE), major bleeding, and death, and the predictors for clinical outcomes in a contemporary Asian cohort of newly diagnosed AF patients.

METHODS

This is a prospective multicenter nationwide registry of patients with AF from 27 hospitals in Thailand. Baseline data and follow-up data were collected every 6 months until 3 years. Data collections included demographic, medical history, laboratory, and medication details. Clinical outcomes were SSE, major bleeding, and all-cause mortality. Incidence rates for each clinical outcome were calculated and presented as rate per 100 person-years. Univariate and multivariate analysis was performed to determine the independent predictors for clinical outcomes.

RESULTS

There was a total of 3405 patients: mean age was 67.8 ± 11.3 years, 1981 (58.2%) were male. During 30.8 ± 9.7 months follow-up, there was a total of 132 SSE (3.9%), 191 major bleeding (5.6%), and 357 all-cause deaths (10.5%). The incidence rates of SSE, major bleeding, and death were 1.56 (1.30-1.84), 2.26 (1.96-2.61), and 4.17 (3.33-4.25), per 100 person-years respectively. Independent predictors for clinical outcomes were age, type of AF, and the presence of comorbid conditions.

CONCLUSION

The incidence rate of SSE, major bleeding, and death remains high reflecting the unmet needs in AF management.

References

[1]

Gibbs H, Freedman B, Rosenqvist M, et al. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: Implications for AF Screening. Am J Med 2021; 134: 893-901 e811.

[2]

Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28, 628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One 2018; 13: e0191592.

[3]

Burdett P, Lip GYH. Atrial fibrillation in the united kingdom: predicting costs of an emerging epidemic recognising and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes 2022; 8: 187−194.

[4]

Piccini JP, Simon DN, Steinberg BA, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol 2016; 1: 282−291.

[5]

Koretsune Y, Etoh T, Katsuda Y, et al. Risk Profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan- Insights From GARFIELD-AF. Circ J 2018; 83: 67−74.

[6]

Fox KAA, Virdone S, Bassand JP, et al. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. BMJ Open 2022; 12: e049933.

[7]

Kim HK, Tantry US, Smith SC Jr, et al. The east asian paradox:an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121: 422−432.

[8]

Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 2015; 180: 246−254.

[9]

Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin k antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 2015; 46: 2555−2561.

[10]

An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes 2019; 5: 35−42.

[11]

Heijman J, Guichard JB, Dobrev D, Nattel S. Translational challenges in atrial fibrillation. Circ Res 2018; 122: 752−773.

[12]

Salih M, Abdel-Hafez O, Ibrahim R, Nair R. Atrial fibrillation in the elderly population: Challenges and management considerations. J Arrhythm 2021; 37: 912−921.

[13]

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 42: 373−498.

[14]

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74: 104−132.

[15]

Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; 154: 1121−1201.

[16]

Chao TF, Joung B, Takahashi Y, et al. 2021 focused update consensus guidelines of the asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122: 20−47.

[17]

Bahuleyan CG, Namboodiri N, Jabir A, et al. One-year clinical outcome of patients with nonvalvular atrial fibrillation: Insights from KERALA-AF registry. Indian Heart J 2021; 73: 56−62.

[18]

Krittayaphong R, Winijkul A, Methavigul K, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord 2018; 18: 174.

[19]

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692−694.

[20]

Ogawa H, Hamatani Y, Doi K, et al. Sex-related differences in the clinical events of patients with atrial fibrillation—The Fushimi AF Registry. Circ J 2017; 81: 1403−1410.

[21]

Chan YH, Lee HF, See LC, et al. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest 2019; 156: 529−543.

[22]

Krittayaphong R, Boonyapiphat T, Wongvipaporn C, et al. Age-related clinical outcomes of patients with non-valvular atrial fibrillation: insights from the COOL-AF Registry. Clin Interv Aging 2021; 16: 707−719.

[23]

Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23−30.

[24]

Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309−315.

[25]

Chao TF, Chen SA, Ruff CT, et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40: 1518−1527.

[26]

Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (age >/= 85 years) japanese patients with atrial fibrillation: the Fushimi AF registry. Chest 2016; 149: 401−412.

[27]

Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14: 627−628.

[28]

Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thromb Haemost 2021; 121: 270−278.

[29]

Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb Haemost 2022; 122: 406−414.

[30]

Yoon M, Yang PS, Jang E, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thromb Haemost 2019; 119: 1695−1703.

[31]

Rasmussen PV, Pallisgaard JL, Hansen ML, et al. Treatment of older patients with atrial fibrillation by morbidity burden. Eur Heart J Qual Care Clin Outcomes 2022; 8: 23−30.

[32]

Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc 2019; 94: 2427−2436.

[33]

An Y, Ogawa H, Esato M, et al. Age-dependent prognostic impact of paroxysmal versus sustained atrial fibrillation on the incidence of cardiac death and heart failure hospitalization (the Fushimi AF Registry). Am J Cardiol 2019; 124: 1420−1429.

[34]

Apiyasawat S, Kornbongkotmas S, Chichareon P, et al. Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry. J Arrhythm 2021; 37: 1434−1442.

Journal of Geriatric Cardiology
Pages 163-173
Cite this article:
Krittayaphong R, Pumprueg S, Kaewkumdee P, et al. Three-year outcomes of patients with non-valvular atrial fibrillation: the COOL-AF registry. Journal of Geriatric Cardiology, 2023, 20(3): 163-173. https://doi.org/10.26599/1671-5411.2023.03.008
Metrics & Citations  
Article History
Copyright
Return